Welcome to our dedicated page for Mdxhealth Sa news (Ticker: MDXH), a resource for investors and traders seeking the latest updates and insights on Mdxhealth Sa stock.
MDxHealth SA (NASDAQ: MDXH) is a precision diagnostics company focused on molecular tests for prostate cancer and other urologic diseases. Its news flow centers on financial performance, clinical evidence generation, and corporate developments that shape its position in urologic oncology. The company regularly reports revenue trends, test volumes across tissue-based and liquid-based assays, adjusted EBITDA metrics, and cash balances under International Financial Reporting Standards (IFRS).
Investors following MDXH news will see updates on quarterly and full-year financial results, including revenue growth driven by tests such as Confirm mdx, the Genomic Prostate Score (GPS) test, Select mdx, Resolve mdx, Germline tests, and the ExoDx Prostate (EPI) test acquired with the Exosome Diagnostics business. Releases often discuss the mix between tissue-based and liquid-based testing, gross margins, operating expenses, and progress toward adjusted EBITDA profitability.
MDxHealth’s news also highlights strategic transactions and partnerships. Recent items include the acquisition and integration of the Exosome Diagnostics business from Bio‑Techne, amendments to earnout terms related to the GPS prostate cancer business acquired from Exact Sciences, and collaborations such as the initiation of GPS testing in the UK ProtecT trial in partnership with the University of Oxford. Governance and leadership changes, such as board appointments and finance leadership transitions, are disclosed through press releases furnished on Form 6-K.
This MDXH news page aggregates these company announcements, earnings releases, acquisition updates, and clinical collaboration milestones in one place, helping readers monitor how MDxHealth’s precision diagnostics portfolio, financial profile, and corporate strategy evolve over time.
MDxHealth (NASDAQ: MDXH) reported preliminary Q4 and full-year 2025 results and issued 2026 revenue guidance. The company expects Q4 2025 revenue of approximately $30.5M and full-year 2025 revenue of $109M, representing year-over-year growth of 23% and 21%, respectively. Volume highlights include 11,201 tissue-based and 27,486 liquid-based units billed in Q4; full-year volumes were 49,180 tissue and 71,920 liquid units. Year-end cash was $29.0M. 2026 revenue guidance is $137–140M (+26–28% YoY). The company amended earnout terms with Exact Sciences: remaining payments of $15.0M (2026), $18.0M (2027), and $21.5M (2028) and issued warrants for 3.0M common shares at a $5.265 exercise price.
mdxhealth (NASDAQ: MDXH) announced initiation of Genomic Prostate Score (GPS) testing in the UK ProtecT randomized trial to validate GPS in an Active Surveillance cohort.
The ProtecT trial followed >1,500 men with localized prostate cancer for over two decades across Active Surveillance, Radical Prostatectomy, and Radiotherapy, providing long-term outcomes that the GPS-ProtecT study will leverage to test GPS's predictive power.
This follows a prior ProMPT validation and aims to generate randomized clinical-trial evidence supporting GPS's clinical utility and potential influence on guidelines, payer coverage, and provider adoption.
mdxhealth (NASDAQ: MDXH) reported Q3 2025 results with revenue $27.4M (+18% YoY), gross margin 65.2% (+4.0pp), and adjusted EBITDA $1.0M. The company reported a Q3 net loss of $8.0M (28% improvement YoY) and cash $32.0M at Sept 30, 2025. On Sept 15, 2025 mdxhealth closed the acquisition of Exosome Diagnostics from Bio-Techne, expanding the direct sales team to 60 reps and adding the ExoDx prostate test to its menu. Management suspended the planned germline product launch to prioritize ExoDx, Confirm mdx and GPS commercial integration.
MDxHealth (NASDAQ: MDXH) will release third quarter 2025 financial results for the period ended September 30, 2025 after market close on Wednesday, November 12, 2025.
The company will host a conference call and webcast with live Q&A on November 12, 2025 at 4:30 PM ET / 22:30 CET. Attendees are asked to access the webcast 15 minutes early. Dial-in numbers are provided for the United States, Belgium, the Netherlands, and the United Kingdom; the conference ID is 10203872. The live webcast URL is https://viavid.webcasts.com/starthere.jsp?ei=1738892&tp_key=76bbbf3f0a. A replay will be available on the company website following the call.
MDxHealth (NASDAQ: MDXH), a precision diagnostics company, has completed the acquisition of the ExoDx business from Bio-Techne Corporation. The acquisition includes the ExoDx Prostate (EPI) test, a CLIA-certified clinical laboratory, and related assets.
The total acquisition value is $15 million, structured as $5 million in stock paid at closing, with the remaining $10 million to be paid over 4 years in annual installments of $2.5 million (50% cash, 50% optional cash or stock). XMS Capital Partners served as financial advisor, while K&L Gates and Baker McKenzie provided legal counsel for the transaction.
MDxHealth (NASDAQ: MDXH) reported strong Q2 2025 results and announced a strategic acquisition. The company achieved $26.6 million in revenue, marking a 20% year-over-year increase and its 17th consecutive quarter of 20%+ growth. Notably, MDxHealth reached positive adjusted EBITDA of $1.4 million in Q2.
The company announced the acquisition of Bio-Techne's ExoDx business for $15 million, to be paid in cash and stock over 5 years. The deal includes the ExoDx Prostate test and CLIA-certified laboratory. The acquisition is expected to contribute over $20 million in revenue by 2026 and accelerate revenue growth to approximately 30%.
Q2 highlights include a 74% improvement in operating loss to $1.9 million, tissue-based test volume growth of 26%, and liquid-based test volume increase of 18%. The company reaffirmed its 2025 revenue guidance of $108-110 million.
MDxHealth (NASDAQ: MDXH), a precision diagnostics company, has announced key leadership changes. Michael Holder, an executive with over 30 years of experience, has been appointed to the Board of Directors as Audit Committee Chair, replacing Regine Slagmulder. Holder brings extensive expertise in corporate strategy, M&A, and governance, currently serving on boards including Cytek Biosciences.
Additionally, CFO Ron Kalfus has resigned effective July 30, 2025, after 6 years with the company. Scott McMahan, Vice President of Finance and Accounting, will assume CFO responsibilities on an interim basis.
MDxHealth, a precision diagnostics company listed on NASDAQ (MDXH), has scheduled the release of its first quarter 2025 financial results for May 14, 2025, after market close. The company will host a conference call and webcast at 4:30pm ET / 22:30 CET on the same day.
CEO Michael K. McGarrity and CFO Ron Kalfus will lead the presentation. Investors can join via multiple regional dial-in numbers:
- United States: 1-844-825-9789
- Belgium: 0800 38 961
- Netherlands: 0800 94 94 506
- United Kingdom: 0808 238 9064
Participants should access the webcast 15 minutes before the start time using Conference ID 10199102. A replay will be available on the company's website after the live call.
MDxHealth (NASDAQ: MDXH) reported strong Q4 and full-year 2024 financial results, with 28% revenue growth in both Q4 ($24.7 million) and full-year ($90.0 million). Q4 highlights include a 68% improvement in adjusted EBITDA to ($1.4) million and significant test volume increases: tissue-based tests up 50% and liquid-based tests up 10%.
Q4 gross profit increased 22% to $15.5 million with margins at 62.7%, while operating expenses rose 6% to $20.1 million. Net loss decreased 36% to $6.8 million. For full-year 2024, gross profit grew 26% to $55.1 million with 61.2% margins, and net loss improved 12% to $38.1 million.
The company maintains its 2025 revenue guidance of $108-110 million and expects to achieve adjusted EBITDA profitability in H1 2025. Year-end cash position stands at $46.8 million.
FAQ
What is the current stock price of Mdxhealth Sa (MDXH)?
What is the market cap of Mdxhealth Sa (MDXH)?
